Non-segmental Vitiligo Clinical Trial
Official title:
ASSESSMENT OF TRISTETRAPROLIN EXPRESSION IN LESIONAL SKIN OF PATIENTS WITH NON SEGMENTAL VITILIGO
Vitiligo is characterized by the selective loss of melanocytes, which in turn leads to totally amelanotic, non-scaly, chalky-white macule with distinct margins Vitiligo is the most common depigmenting skin disorder, with an estimated prevalence of 0.5-2% of the population in both adults and children worldwide Tumor necrosis factor (TNF-α), a pro-inflammatory cytokine is necessary for Th1 mediated response and immune homeostasis and the up-regulation of TNF-α can result in chronic inflammatory and autoimmune diseases . previous studies revealed a rise in transcript and protein levels of TNF-α in vitiligo patients The prime location of melanocytes, keratinocytes and fibroblasts is the epidermal microenvironment and these cells are capable of TNF-α expression and secretion TNF-α acts as an autocrine as well as a paracrine manner to suppress the melanocyte growth and proliferation ( Tristetraprolin (TTP) zinc finger protein 36 (ZFP36) is Ribonucleic acid (RNA) binding protein that preferentially binds to Adenylate-uridylate-rich (AU-rich) regions in the 3' untranslated regions (3'UTR) of target genes . Additionally, Tristetraprolin functions by destabilizing mRNAs encoding for oncogenes, cytokines (as TNFα), and chemokines involved in the inflammatory processes, by favoring their degradation and/or preventing their efficient translation The expression of proinflammatory mediator genes is tightly controlled by post-transcriptional regulation, which is mediated by a set of immune-related RNA binding proteins, such as tristetraprolin, Roquin, and Regnase
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04052425 -
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)
|
Phase 3 | |
| Completed |
NCT04057573 -
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)
|
Phase 3 | |
| Completed |
NCT04942860 -
The Evaluation of Vitiligous Lesions Repigmentation After Topical Administration of Methotrexate in Patients With Active Vitiligo
|
Phase 3 | |
| Recruiting |
NCT06113328 -
A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)
|
Phase 2 | |
| Recruiting |
NCT01377077 -
Punchgrafting Techniques for Vitiligo
|
Phase 4 | |
| Completed |
NCT04927975 -
Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo
|
Phase 2 | |
| Completed |
NCT04487860 -
Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo
|
Phase 2 | |
| Active, not recruiting |
NCT04811326 -
Latanoprost Plus NB-UVB Versus Each Alone in Non-segmental Vitiligo: Clinical and Laboratory Evaluation
|
Phase 4 | |
| Terminated |
NCT03022019 -
ReNovaCell in Non-segmental Vitiligo
|
N/A | |
| Completed |
NCT03247400 -
The Evaluation of Vitiligous Lesions Repigmentation After the Administration of Atorvastatin Calcium Salt and Simvastatin-acid Sodium Salt in Patients With Active Vitiligo
|
Phase 1/Phase 2 |